JP2004508808A5 - - Google Patents

Download PDF

Info

Publication number
JP2004508808A5
JP2004508808A5 JP2001577501A JP2001577501A JP2004508808A5 JP 2004508808 A5 JP2004508808 A5 JP 2004508808A5 JP 2001577501 A JP2001577501 A JP 2001577501A JP 2001577501 A JP2001577501 A JP 2001577501A JP 2004508808 A5 JP2004508808 A5 JP 2004508808A5
Authority
JP
Japan
Prior art keywords
retroviral
nucleotide sequence
gag
viral
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001577501A
Other languages
English (en)
Japanese (ja)
Other versions
JP4981231B2 (ja
JP2004508808A (ja
Filing date
Publication date
Priority claimed from GBGB0009760.0A external-priority patent/GB0009760D0/en
Application filed filed Critical
Publication of JP2004508808A publication Critical patent/JP2004508808A/ja
Publication of JP2004508808A5 publication Critical patent/JP2004508808A5/ja
Application granted granted Critical
Publication of JP4981231B2 publication Critical patent/JP4981231B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2001577501A 2000-04-19 2001-04-18 レトロウイルスパッケージング細胞での発現のためのコドン最適化 Expired - Lifetime JP4981231B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0009760.0 2000-04-19
GBGB0009760.0A GB0009760D0 (en) 2000-04-19 2000-04-19 Method
PCT/GB2001/001784 WO2001079518A2 (en) 2000-04-19 2001-04-18 Codon optimisation for expression in retrovirus packaging cells

Publications (3)

Publication Number Publication Date
JP2004508808A JP2004508808A (ja) 2004-03-25
JP2004508808A5 true JP2004508808A5 (https=) 2008-04-03
JP4981231B2 JP4981231B2 (ja) 2012-07-18

Family

ID=9890278

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001577501A Expired - Lifetime JP4981231B2 (ja) 2000-04-19 2001-04-18 レトロウイルスパッケージング細胞での発現のためのコドン最適化

Country Status (14)

Country Link
US (3) US20050042234A1 (https=)
EP (2) EP2194137B1 (https=)
JP (1) JP4981231B2 (https=)
CN (2) CN101024845B (https=)
AT (1) ATE462796T1 (https=)
AU (1) AU4861901A (https=)
CA (1) CA2404129A1 (https=)
CY (1) CY1110123T1 (https=)
DE (1) DE60141690D1 (https=)
DK (2) DK1278878T3 (https=)
ES (2) ES2618508T3 (https=)
GB (1) GB0009760D0 (https=)
PT (1) PT1278878E (https=)
WO (1) WO2001079518A2 (https=)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
US9738907B2 (en) 2002-02-01 2017-08-22 Oxford Biomedica (Uk) Limited Viral vector
EP1504108B1 (en) * 2002-02-01 2013-04-17 Oxford Biomedica (UK) Limited Lentiviral vector
JP2005533485A (ja) * 2002-02-04 2005-11-10 ノバルティス アクチエンゲゼルシャフト 組換えウシ免疫不全ウイルスに基づく遺伝子導入システム
CN1980955A (zh) * 2004-04-29 2007-06-13 北卡罗来纳-查佩尔山大学 增强细胞粘连特性的方法和组合物
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
PL2307551T3 (pl) 2008-06-18 2017-07-31 Oxford Biomedica (Uk) Limited Oczyszczanie wektorów retrowirusowych
CN102946907A (zh) 2010-05-28 2013-02-27 牛津生物医学(英国)有限公司 慢病毒载体向脑的递送
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
CA2909733C (en) 2013-04-18 2023-10-17 Fondazione Telethon Effective delivery of large genes by dual aav vectors
ES2747951T3 (es) 2013-10-24 2020-03-12 Ospedale San Raffaele Srl Método
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
SI3194434T1 (sl) 2014-09-15 2019-11-29 Molmed Spa Himerni antigenski receptorji
GB201418965D0 (https=) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
GB201519086D0 (en) 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
US20190017096A1 (en) 2016-03-10 2019-01-17 Nightstarx Limited Prenylation assay
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
EP3235828A1 (en) * 2016-04-21 2017-10-25 Genethon Stable pseudotyped lentiviral particles and uses thereof
EP3318285A1 (en) 2016-11-08 2018-05-09 Oxford University Innovation Limited Treatment of eye disease
WO2018099933A1 (en) 2016-12-01 2018-06-07 Nestec S.A. Methods of modulating fam46a
CN108130333A (zh) * 2016-12-01 2018-06-08 上海泽润生物科技有限公司 重组脊髓灰质炎ⅰ型病毒样颗粒
EP3375876A1 (en) 2017-03-13 2018-09-19 Evonetix Ltd Method for producing double stranded polynucleotides based on oligonucleotides with selected and different melting temperatures
CA3056542A1 (en) 2017-03-15 2018-09-20 Oxford Biomedica (Uk) Limited Method
CN110475865A (zh) 2017-03-31 2019-11-19 雀巢产品有限公司 调节ank1的方法
GB201706121D0 (en) * 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Stable cell lines for retroviral production
PT3612624T (pt) 2017-04-21 2024-11-29 Ospedale San Raffaele Srl Terapia génica
WO2018197492A1 (en) 2017-04-24 2018-11-01 Ospedale San Raffaele S.R.L. Tcr and peptides
WO2019068854A1 (en) 2017-10-06 2019-04-11 Ospedale San Raffaele S.R.L. GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS
JP2021502820A (ja) 2017-10-17 2021-02-04 ナイトスタアールエックス リミテッド プレニル化アッセイ
JP7477448B2 (ja) 2017-11-21 2024-05-01 ソシエテ・デ・プロデュイ・ネスレ・エス・アー Alkを調節する方法
GB201720948D0 (en) * 2017-12-15 2018-01-31 Autolus Ltd Plasmid system
EP3633040B1 (en) 2017-12-22 2023-06-07 Oxford BioMedica (UK) Limited Retroviral vector
WO2019134866A1 (en) 2018-01-03 2019-07-11 Molmed Spa Chimeric antigen receptors containing optimal spacer region
AU2019254824B2 (en) 2018-04-18 2025-04-24 Ucl Business Ltd Method for enhancing the suppressive properties of Treg cells
AU2019269593A1 (en) 2018-05-15 2020-11-26 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
WO2019219308A1 (en) 2018-05-17 2019-11-21 Societe Des Produits Nestle S.A. Methods of modulating nkx6.3
JP2021525066A (ja) 2018-05-30 2021-09-24 グリコステム セラピューティクス ベスローテン フェンノートシャップ Car nk細胞
EP3820509A1 (en) 2018-07-09 2021-05-19 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
GB201814203D0 (en) 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
GB201817821D0 (en) 2018-10-31 2018-12-19 Ospedale San Raffaele Srl TCR and peptides
EP3880832A1 (en) 2018-11-14 2021-09-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
SG11202105079QA (en) 2018-11-14 2021-06-29 Flagship Pioneering Innovations V Inc Fusosome compositions for cns delivery
WO2020102503A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for t cell delivery
GB201900687D0 (en) 2019-01-17 2019-03-06 King S College London Immunotherapeutic methods and compositions
WO2020128478A1 (en) 2018-12-19 2020-06-25 King's College London Immunotherapeutic methods and compositions
GB201902277D0 (en) 2019-02-19 2019-04-03 King S College London Therapeutic agents
US20220175962A1 (en) 2019-03-10 2022-06-09 Sio Gene Therapies Inc. Gene therapy compositions and methods for treating parkinson's disease
GB201905301D0 (en) 2019-04-15 2019-05-29 Ospedale San Raffaele Srl Gene therapy
GB201907493D0 (en) 2019-05-28 2019-07-10 Ospedale San Raffaele Agents and methods for treating viral infections
GB201912515D0 (en) 2019-08-30 2019-10-16 King S College London Engineered regulatory T cell
AU2020341454A1 (en) 2019-09-03 2022-03-10 Sana Biotechnology, Inc. CD24-associated particles and related methods and uses thereof
WO2021094752A1 (en) 2019-11-12 2021-05-20 Oxford Biomedica (Uk) Limited Production system
JP2023513303A (ja) 2020-02-13 2023-03-30 オックスフォード バイオメディカ(ユーケー)リミテッド レンチウイルスベクターの製造
CN115427440A (zh) 2020-02-25 2022-12-02 圭尔医疗有限公司 用于工程化细胞的嵌合受体
US20230118587A1 (en) 2020-03-13 2023-04-20 Oxford Biomedica (Uk) Limited Lentiviral Vectors
JP2023521663A (ja) 2020-03-31 2023-05-25 サナ バイオテクノロジー,インコーポレイテッド 標的化脂質粒子及び組成物ならびにその使用
GB202007169D0 (en) 2020-05-14 2020-07-01 Ospedale San Raffaele Srl Epidermal growth factor receptor
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
WO2021236852A1 (en) 2020-05-20 2021-11-25 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
GB202013477D0 (en) 2020-08-27 2020-10-14 Quell Therapeutics Ltd Nucleic acid constructs for expressing polypeptides in cells
US20230303665A1 (en) 2020-08-28 2023-09-28 Sana Biotechnology, Inc. Modified anti-viral binding agents
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
GB202018657D0 (en) 2020-11-26 2021-01-13 Ospedale San Raffaele Srl Agents and methods for increasing liver immune response
CN112430582B (zh) * 2020-12-04 2022-05-03 北京艺妙神州医药科技有限公司 一种慢病毒稳定包装细胞系及其制备方法
US20240052015A1 (en) 2020-12-23 2024-02-15 Quell Therapeutics Limited Inducible signalling protein
EP4274901A1 (en) 2021-01-11 2023-11-15 Sana Biotechnology, Inc. Use of cd8-targeted viral vectors
KR20230152689A (ko) 2021-02-01 2023-11-03 엡실렌 바이오 에스.알.엘. 유전자 침묵
KR20230171424A (ko) 2021-02-15 2023-12-20 오스페달레 산 라파엘 에스.알.엘. 암의 치료를 위한 후성적 침묵
GB202102637D0 (en) 2021-02-24 2021-04-07 Quell Therapeutics Ltd Engineered regulatory t cell
GB202102832D0 (en) * 2021-02-26 2021-04-14 Ip2Ipo Innovations Ltd Retroviral vectors
MX2023013393A (es) 2021-05-12 2023-12-08 Fond Telethon Sistema de vectores.
AU2022280957A1 (en) 2021-05-28 2023-11-30 Sana Biotechnology, Inc. Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses
WO2023015217A1 (en) 2021-08-04 2023-02-09 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
TW202321286A (zh) 2021-09-21 2023-06-01 英商圭爾醫療有限公司 抗p75ntr嵌合抗原受體
WO2023047100A1 (en) 2021-09-21 2023-03-30 Quell Therapeutics Ltd Anti-trem2 chimeric antigen receptor
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
US20250230511A1 (en) 2021-10-29 2025-07-17 Sana Biotechnology, Inc. Methods and reagents for amplifying viral vector nucleic acid products
GB202117298D0 (en) 2021-11-30 2022-01-12 Quell Therapeutics Ltd Signalling protein
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
US20250059560A1 (en) 2021-12-16 2025-02-20 Sana Biotechnology, Inc. Methods and systems of particle production
US20250059239A1 (en) 2021-12-17 2025-02-20 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
EP4448775A1 (en) 2021-12-17 2024-10-23 Sana Biotechnology, Inc. Modified paramyxoviridae attachment glycoproteins
CN118434761A (zh) 2021-12-22 2024-08-02 圭尔医疗有限公司 组成型细胞因子受体
WO2023131657A1 (en) 2022-01-05 2023-07-13 Gyala Therapeutics Sociedad Limitada Anti-cd84 antibodies and chimeric antigen receptors
EP4209511A1 (en) 2022-01-05 2023-07-12 Gyala Therapeutics Sociedad Limitada Anti-cd84 antibodies amd chimeric antigen receptors
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
EP4472646A1 (en) 2022-02-01 2024-12-11 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
US20250144235A1 (en) 2022-02-02 2025-05-08 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
EP4269426A1 (en) 2022-04-29 2023-11-01 Ospedale San Raffaele S.r.l. Gene therapy
EP4303226A1 (en) 2022-07-08 2024-01-10 Ospedale San Raffaele S.r.l. Transgene cassettes and epigenetic silencers for the treatment of disorders
EP4551253A1 (en) 2022-07-08 2025-05-14 Ospedale San Raffaele S.r.l. Transgene cassettes
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024033544A1 (en) 2022-08-12 2024-02-15 Ospedale San Raffaele S.R.L. Deglycosylation of native glycoproteins expressed on a tumor cell surface
GB202211935D0 (en) 2022-08-16 2022-09-28 Oxford Biomedica Ltd envelope proteins
US20260055146A1 (en) 2022-08-24 2026-02-26 Sana Biotechnology, Inc. Delivery of heterologous proteins
US20260098062A1 (en) 2022-09-21 2026-04-09 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
EP4615492A1 (en) 2022-11-08 2025-09-17 Ospedale San Raffaele S.r.l. Polynucleotide and vector
WO2024100294A1 (en) 2022-11-11 2024-05-16 Ospedale San Raffaele S.R.L. Cdh17 car
GB202217541D0 (en) 2022-11-24 2023-01-11 Quell Therapeutics Ltd Recombinant receptor
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024133472A1 (en) 2022-12-22 2024-06-27 Quell Therapeutics Limited Constitutive cytokine receptors
WO2024153644A1 (en) 2023-01-16 2024-07-25 Ospedale San Raffaele S.R.L. T-cell receptors
EP4403580A1 (en) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
KR20250169635A (ko) 2023-01-23 2025-12-03 메디치니쉐 호흐슐레 하노버 항-entpd3 키메라 항원 수용체
IL322333A (en) 2023-02-07 2025-09-01 Quell Therapeutics Ltd Culture method for TREG cells
EP4669343A1 (en) 2023-02-24 2025-12-31 Medizinische Hochschule Hannover CHIMERIC ANTIGEN RECIPIENT
EP4420676A1 (en) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024194223A2 (en) 2023-03-17 2024-09-26 Ospedale San Raffaele S.R.L. Gene therapy
EP4680728A1 (en) 2023-03-17 2026-01-21 Quell Therapeutics Limited Treg therapy
EP4434539A1 (en) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Chimeric antigen receptor
CN121586582A (zh) 2023-03-20 2026-02-27 汉诺威医学院 嵌合抗原受体
WO2024194642A1 (en) 2023-03-22 2024-09-26 Quell Therapeutics Limited Engineered t regulatory cell
WO2024194649A1 (en) 2023-03-22 2024-09-26 Quell Therapeutics Limited Engineered t cells and uses thereof
CN121219020A (zh) 2023-03-22 2025-12-26 圣拉斐尔医院有限责任公司 基因疗法
EP4698666A1 (en) 2023-04-18 2026-02-25 Sana Biotechnology, Inc. Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
EP4698665A1 (en) 2023-04-18 2026-02-25 Sana Biotechnology, Inc. Engineered protein g fusogens and related lipid particles and methods thereof
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
GB202307366D0 (en) 2023-05-17 2023-06-28 Ospedale San Raffaele Srl Vector
KR20260016952A (ko) 2023-05-23 2026-02-04 사나 바이오테크놀로지, 인크. 탠덤 퓨소젠 및 관련 지질 입자
EP4731648A1 (en) 2023-06-21 2026-04-29 Quell Therapeutics Limited Constitutive cytokine receptors
AU2024305679A1 (en) 2023-06-28 2026-01-22 Ospedale San Raffaele S.R.L. T-cell receptors
WO2025032194A1 (en) 2023-08-08 2025-02-13 Ospedale San Raffaele S.R.L. T-cell receptors
GB202316264D0 (en) 2023-10-24 2023-12-06 Ospendale San Raffaele S R L Gene therapy
IT202300022191A1 (it) 2023-10-24 2025-04-24 Fond Telethon Ets Mezzi e metodi per la modifica genetica di uba1
WO2025109189A1 (en) 2023-11-24 2025-05-30 Ospedale San Raffaele S.R.L. Engineered regulatory t cells and uses thereof
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
EP4640830A1 (en) 2024-04-23 2025-10-29 Fondazione Telethon ETS Means and methods for safe and efficient gene editing in cells
WO2026008994A1 (en) 2024-07-04 2026-01-08 Quell Therapeutics Limited Expression construct
WO2026027876A1 (en) 2024-07-29 2026-02-05 Quell Therapeutics Limited Chimeric antigen receptor
GB202411558D0 (en) 2024-08-06 2024-09-18 Quell Therapeutics Ltd Culture method
GB202415025D0 (en) 2024-10-11 2024-11-27 Ospedale San Raffaele Srl Cell

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU611925B2 (en) 1987-07-29 1991-06-27 Basf Lacke & Farben Aktiengesellschaft Aqueous electro-dipcoat baths containing cathodically depositable synthetic resins and process for coating electrically conductive substrates
WO1991000047A1 (en) 1989-06-30 1991-01-10 The Regents Of The University Of California Retrovirus detection
EP1285967A3 (en) 1990-09-21 2005-03-02 Chiron Corporation Human retroviral packaging cell line
US6013517A (en) * 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
AU3635695A (en) 1994-09-19 1996-04-09 Board Of Trustees Of The Leland Stanford Junior University Methods for genetically modifying hematopoietic stem cells
US5786464C1 (en) * 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
CA2237000A1 (en) 1995-11-08 1997-05-15 The Whitehead Institute For Biomedical Research Stable packaging cell line producing pseudotyped retroviruses
US5739018A (en) 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
US6133027A (en) 1996-08-07 2000-10-17 City Of Hope Inducible expression system
DE69729007T2 (de) 1996-08-07 2005-04-07 Darwin Discovery Ltd., Slough Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
US6696291B2 (en) * 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
JP4390860B2 (ja) * 1997-05-13 2009-12-24 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル レンチウイルスをベースにした遺伝子転移ベクター
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
CN1303442A (zh) 1997-09-23 2001-07-11 牛津生物医学(英国)有限公司 方法
ES2373406T3 (es) * 1997-12-22 2012-02-03 Oxford Biomedica (Uk) Limited Vectores basados en el virus de la anemia infecciosa equina (vaie).
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6958226B1 (en) * 1998-09-11 2005-10-25 The Children's Medical Center Corp. Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins
AU6139699A (en) * 1998-09-11 2000-04-03 Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
WO2000039302A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
GB9906177D0 (en) * 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
PL351988A1 (en) * 1999-04-26 2003-07-14 Leuven K U Res & Dev Synthetic gene for expressing active retroviral protein in eukaryotes
GB9923558D0 (en) * 1999-10-05 1999-12-08 Oxford Biomedica Ltd Producer cell

Similar Documents

Publication Publication Date Title
JP2004508808A5 (https=)
JP2002503477A5 (https=)
Maurer et al. Analysis of the primary structure of the long terminal repeat and the gag and pol genes of the human spumaretrovirus
GB2630191A (en) Self-assembling virus-like particles for delivery of prime editors and methods of making and using same
CN102227501B (zh) 基因治疗载体和胞嘧啶脱氨酶
JP2023106545A (ja) ACE-tRNAを用いた遺伝的再帰属を介して終止コドンレスキューする方法
GB2630190A (en) Self-assembling virus-like particles for delivery of nucleic acid programmable fusion proteins and methods of making and using the same
Sagata et al. Comparison of the entire genomes of bovine leukemia virus and human T‐cell leukemia virus and characterization of their unidentified open reading frames.
US5886166A (en) Retroviral vector, a replication system for said vector and avian or mammalian cells transfected with said vector
JP2004520016A5 (https=)
Cherepanov et al. High‐level expression of active HIV‐1 integrase from a synthetic gene in human cells
CA2298892A1 (en) Lentiviral vectors derived from sivagm, methods for their preparation and their use for gene transfer into mammalian cells
RU2009130342A (ru) Применение адаптированных рекомбиназ для лечения ретровирусных инфекций
Kato et al. The entire nucleotide sequence of baboon endogenous virus DNA: a chimeric genome structure of murine type C and simian type D retroviruses
EP0611822B1 (en) More complex type retroviruses having mixed type LTR, and uses thereof
JP2004509601A5 (https=)
ES2683820T3 (es) Uso de proteínas GAG no de subtipo B para encapsidación lentiviral
CA2394261A1 (en) Fusion protein delivery system and uses thereof
CN116554349A (zh) 嵌合病毒包膜糖蛋白及包含其的载体
US7531353B1 (en) Non self-inactivating, expression targeted retroviral vectors
JPWO2023102537A5 (https=)
WO2009087110A1 (en) Secretable hiv entry inhibitory peptides for therapy of hiv infection
Pérot et al. From viruses to genes: syncytins
Laco et al. Analysis of the proteolytic processing and activation of the rice tungro bacilliform virus reverse transcriptase
WO2001046408A2 (en) Molecular clones with mutated hiv gag/pol, siv gag and siv env genes